On November 28, Gelonghui reported that德琪医药-B (06996.HK) announced that the new indication for希维奥 (Selinexor tablets) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two lines of systemic treatment has been included in the National Healthcare Security Administration's medication catalog (NRDL) for 2024, which will take effect on January 1, 2025.
德琪医药-B(06996.HK)：希维奥用于治疗弥漫大B细胞淋巴瘤的适应症成功纳入2024年版国家医保药品目录
Duke Medical-B (06996.HK): The indication for the use of Xiwei'ao in the treatment of diffuse large B-cell lymphoma has been successfully included in the 2024 version of the national medical insurance pharmaceutical directory.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated